和黄医药
HCM
14.05
+0.11
+0.79%
和黄医药
US · HCM
#2639 按市值排名
上市于 2016
14.05
+0.11
+0.79%
实时 - 追踪5344个代码 - 心跳于315秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 57.29% -0.08pp
- 机构数量
- 139
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund38.27%
Mutual Fund17.59%
Sovereign Wealth Fund1.01%
Individual/Insider0.97%
Private Company0.26%
Hedge Fund0.15%
Other41.74%
主要股东 截至 2026-06-30
Hutchison Whampoa (China) Limited
38.26% · 66.51M 股
China Universal Asset Management Company Ltd.
2.44% · 4.24M 股
Vanguard Capital Management, LLC
2.18% · 3.78M 股
BlackRock
1.42% · 2.46M 股
GF Fund Management Co., Ltd.
1.22% · 2.12M 股
Norges Bank Investment Management
1.01% · 1.75M 股
Penghua Fund Management Co., Ltd.
0.92% · 1.59M 股
Yinhua Fund Management Co., Ltd.
0.86% · 1.50M 股
Schroder Investment Management (Singapore) Ltd.
0.85% · 1.48M 股
Dacheng Fund Management Co., Ltd.
0.79% · 1.37M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪33份申报 · 8次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Hutchison Whampoa (China) Limited | -- | 38.26% |
| Wei-Guo Su | CEO, Chief Scientific Officer & Executive Director | 0.55% |
| Chig Fung Cheng | Chief Financial Officer | 0.20% |
| Edith Shih | Company Secretary & Non-Executive Director | 0.14% |
| Charles George Rupert Nixon | Group General Counsel | 0.04% |
| Dan Eldar | Non-Executive Director | 0.02% |
| Shu Mok | Independent Non-Executive Director | 0.02% |
| Lorenso Chiu | Deputy Chief Financial Officer | 0.01% |
| Renu Bhatia | Independent Non-Executive Director | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-05-19 | Wei-Guo Su | CEO, Chief Scientific Officer & Executive Director | Other Derivative Acquisition | +75,140 | -- |
| 2026-05-19 | Wei-Guo Su | CEO, Chief Scientific Officer & Executive Director | Other Derivative Acquisition | +132,864 | -- |
| 2026-05-19 | Chig Fung Cheng | Chief Financial Officer | Other Derivative Acquisition | +26,307 | -- |
| 2026-05-19 | Chig Fung Cheng | Chief Financial Officer | Other Derivative Acquisition | +30,157 | -- |
| 2026-05-19 | Charles George Rupert Nixon | Group General Counsel | Other Derivative Acquisition | +7,445 | -- |
| 2026-05-19 | Charles George Rupert Nixon | Group General Counsel | Other Derivative Acquisition | +7,644 | -- |
| 2026-05-19 | Lorenso Chiu | Deputy Chief Financial Officer | Other Derivative Acquisition | +5,176 | -- |
| 2026-05-19 | Lorenso Chiu | Deputy Chief Financial Officer | Other Derivative Acquisition | +8,863 | -- |
| 2026-03-30 | Charles George Rupert Nixon | Group General Counsel | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Lorenso Chiu | Deputy Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-15 | Wei-Guo Su | CEO, Chief Scientific Officer & Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-10 | Chig Fung Cheng | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-09 | Dan Eldar | Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-09 | Edith Shih | Company Secretary & Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-09 | Shu Mok | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-09 | Renu Bhatia | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
和黄医药 讨论区 0 条评论